secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-07-08T20:05:18+00:00
Accession:  0001193125-26-298525
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics stockholders approve 900k share increase to 2025 Incentive Award Plan
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2025 Incentive Award Plan, increasing shares available by 900,000.
- Three Class II directors elected: Stephen A. Berenson, Claire M. Fraser, Ph.D., Richard N. Kender.
- Advisory vote on executive compensation passed with 3,374,813 for, 620,353 against.
- Ratification of PwC as auditor for FY2026 approved with 4,542,915 for, 267,601 against.
- Meeting had 51.75% quorum (4,985,176 shares represented).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/0001193125-26-298525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/d100733d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-298525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer